New Mexico House Bill HB336

New Mexico 2026 Regular Session

• Introduced: 2/4/26

Caption

Use Of Fda-approved Psilocybin

Impact

If passed, HB336 would significantly alter the landscape of mental health treatment within New Mexico. The legislation not only paves the way for the incorporation of synthetic psilocybin into therapeutic practices but also necessitates updates to the existing frameworks in the Controlled Substances Act. This change would provide healthcare professionals the opportunity to engage with innovative treatment modalities that may have previously been restricted, potentially improving patient outcomes in underserved areas of mental health care.

Summary

House Bill 336 seeks to amend the New Mexico Controlled Substances Act to allow for the use of synthetic psilocybin and drugs containing synthetic psilocybin that are approved by the Federal Food and Drug Administration (FDA). This legislative proposal responds to the growing interest in the therapeutic potential of psychedelics, particularly psilocybin, for various mental health conditions such as anxiety, depression, and PTSD. By permitting the use of these FDA-approved substances, the bill aims to enhance treatment options for residents of New Mexico, aligning state law with evolving federal standards.

Contention

Despite the potential benefits, the bill is likely to face scrutiny and debates surrounding public safety, regulatory oversight, and the implications of introducing synthetic psychedelics into therapeutic settings. Opponents may express concerns regarding the risk of abuse and dependency associated with these substances, calling for more comprehensive research and caution in approving such substances for public use. The preemptive alignment with FDA regulations could also raise questions about the state’s autonomy in regulating substances typically deemed harmful.